Novavax Inc (NVAX NASDAQ) stock market data APIs
$6.8417
-0.03(-0.4%)
as of December 5, 2025
Try our APIs with
free plan!
Novavax Inc Financial Data Overview
Price chart is built with
Anychart
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Prev. Close
6.8417
Open
6.8116
High
6.8659
Low
6.7484
52 wk Range
5.01-11.55
Market Cap
1 123 M
P/E Ratio
3.4378
Shares Outstanding
162 M
Revenue
1 065 M
EPS
-1.25
Beta
2.309
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Novavax Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novavax Inc data using free add-ons & libraries
Get Novavax Inc Fundamental Data
Novavax Inc Fundamental data includes:
- Net Revenue: 1 065 M
- EBITDA: 452 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.5427
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novavax Inc News
New
Novavax, Inc. (NVAX): A Bull Case Theory
We came across a bullish thesis on Novavax, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on NVAX. Novavax, Inc.'s share was trading at $6.69 as of Dece...
Former FDA commissioners castigate plan to change vaccine approval standards
[A cup of coffee, glasses and newspaper titled Health Medical] Stadtratte/iStock via Getty Images A dozen former FDA commissioners have come together to pen a scathing op-ed opposing a plan recently ...
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
Shares of prominent vaccine makers Moderna MRNA, BioNTech BNTX, Pfizer PFE, Novavax NVAX and Vaxcyte PCVX fell on Monday after the FDA announced plans to impose strict new vaccine requirements. What�...
Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10
Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
